(Q39905835)

15 September 2017

Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease (English)

1 reference

15 September 2017

1 reference

1

M Flint Beal

1 reference

15 September 2017

1 December 2009

1 reference

Parkinsonism and Related Disorders

15 September 2017

1 reference

15 September 2017

15 Suppl 3

1 reference

15 September 2017

S189-94

1 reference

Mitochondria take center stage in aging and neurodegeneration

15 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

The role of mitochondria in inherited neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Chronic systemic pesticide exposure reproduces features of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Trichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Familial multisystem degeneration with parkinsonism associated with the 11778 mitochondrial DNA mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Mitochondrial DNA polymerase gamma variants in idiopathic sporadic Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

1 reference

7 January 2021

alpha-synuclein promotes mitochondrial deficit and oxidative stress

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Mice lacking alpha-synuclein are resistant to mitochondrial toxins

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

The kinase domain of mitochondrial PINK1 faces the cytoplasm

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

PINK1 in mitochondrial function

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Parkin is recruited selectively to impaired mitochondria and promotes their autophagy

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Neuroprotective effects of creatine administration against NMDA and malonate toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Therapeutic effects of coenzyme Q10 in neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Mitochondria-targeted cytoprotective peptides for ischemia-reperfusion injury

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

PGC-1alpha, a new therapeutic target in Huntington's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Sirtuins: the 'magnificent seven', function, metabolism and longevity

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970812-0

7 January 2021

10.1016/S1353-8020(09)70812-0

Identifiers

DOI

1 reference

15 September 2017

1 reference

PubMed ID

20082988